RecruitingPhase 4NCT06317805

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

Studying Drug- or toxin-induced pulmonary arterial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AOP Orphan Pharmaceuticals AG
Intervention
Generic treprostinil sodium + Standard of Care (Double Oral)(drug)
Enrollment
110 enrolled
Eligibility
18-70 years · All sexes
Timeline
20232027

Study locations (19)

Collaborators

ANOVA CRO s.r.o. · PharmaLex Belgium · Aixial s.r.o. · GCP-Service International Ltd. & Co. KG

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06317805 on ClinicalTrials.gov

Other trials for Drug- or toxin-induced pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Drug- or toxin-induced pulmonary arterial hypertension

← Back to all trials